pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Testosterone Par
drug
save

Testim

Marketedupdated 5mo ago
by Par Pharmaceutical Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • drugtestosterone54 co-mentions · 51 sources
  • drugVogelxo54 co-mentions · 51 sources
  • drugBio T54 co-mentions · 51 sources
  • tagRecall45 co-mentions · 44 sources
  • tagApproval12 co-mentions · 6 sources
  • drugtriamcinolone acetonide Rising10 co-mentions · 10 sources
  • drugTRIAMCINOLONE ACETONIDE10 co-mentions · 10 sources
  • drugtriamcinolone acetonide ER10 co-mentions · 10 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Testim

  • phase2Working Out M0 Bipolar Androgen Therapyrecruitingn=69
  • phase2Supraphysiologic Testosterone Priming Induces Darolutamide Extended Responserecruitingn=60
  • phase352 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadismrecruitingn=100
  • phase2Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)active not recruitingn=51
  • phase2Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancerrecruitingn=50
  • phase4Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Mennot yet recruitingn=144
  • phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCrecruitingn=26
  • phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancercompletedn=36

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 12, 2026
16 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (38)

  • Mar 17, 2034method-of-use (U-1616)US 11090312
  • Mar 17, 2034method-of-use (U-4367)US 11744838
  • Feb 11, 2034formulationUS 8785426
  • Feb 11, 2034formulationUS 8785426
  • Feb 11, 2034formulationUS 9295675
  • Feb 11, 2034formulationUS 9295675
  • Feb 11, 2034formulationUS 9662340
  • Feb 11, 2034formulationUS 9662340
  • Sep 27, 2027method-of-use (U-1390)US 84359441.0y
  • Feb 26, 2027method-of-use (U-1386)US 8419307153d
  • Feb 26, 2027formulationUS 8807861153d
  • Feb 26, 2027method-of-use (U-1390)US 9289586153d
  • Oct 12, 2026formulationUS 846613616d
  • Oct 12, 2026formulationUS 846613616d
  • Oct 12, 2026formulationUS 846613616d
  • Oct 12, 2026method-of-use (U-1103)US 846613716d
  • Oct 12, 2026method-of-use (U-1103)US 846613716d
  • Oct 12, 2026method-of-use (U-1103)US 846613716d
  • Oct 12, 2026method-of-use (U-1103)US 846613816d
  • Oct 12, 2026method-of-use (U-1103)US 846613816d
  • Oct 12, 2026method-of-use (U-1103)US 846613816d
  • Oct 12, 2026formulationUS 848692516d
  • Oct 12, 2026formulationUS 848692516d
  • Oct 12, 2026formulationUS 848692516d
  • Oct 12, 2026formulationUS 872905716d
  • Oct 12, 2026formulationUS 872905716d
  • Oct 12, 2026formulationUS 872905716d
  • Oct 12, 2026method-of-use (U-1103)US 874188116d
  • Oct 12, 2026method-of-use (U-1103)US 874188116d
  • Oct 12, 2026method-of-use (U-1103)US 874188116d
  • Oct 12, 2026formulationUS 875407016d
  • Oct 12, 2026formulationUS 875407016d
  • Oct 12, 2026formulationUS 875407016d
  • Oct 12, 2026formulationUS 875932916d
  • Oct 12, 2026formulationUS 875932916d
  • Oct 12, 2026formulationUS 875932916d
  • Jun 2, 2026method-of-use (U-1390)US 8993520
  • Jun 2, 2026method-of-use (U-1390)US 9180194

News(10)

  • Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
    Two former FDA commissioners: Heidi Overton is the right pick in a difficult moment.
    stat · 3d ago
  • Opinion: More young men are coming to me for plastic surgery. The way I think about them has changed
    “The young men in my clinic are responding rationally to a system that was designed for profit,” writes plastic surgeon Kavitha Ranganathan.
    stat · 7d ago
  • This Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and more
    This week, a Senate committee scheduled a hearing for President Trump’s nominee to lead FDA, new reporting sheds light on the agency’s hiring challenges, and the agency held two meetings to conside…
    raps · 8d ago
  • Disabled workers at greater risk of losing health insurance
    An organ transplant first, new details on ADA conference controversy, and more health news from Morning Rounds
    stat · 21d ago
  • A new, separate outbreak of the diarrhea-causing parasite
    A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
    stat · 2mo ago
  • Expect a clash at today’s FDA peptide panel
    The service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning Rounds
    stat · 2mo ago
  • Opinion: Good riddance to bundled ‘global’ maternal care billing
    New maternal billing codes should create a transparent system where both patients and clinicians can thrive, ACOG writes.
    stat · 2mo ago
  • Opinion: New billing codes likely to raise maternity care costs
    “This change is likely to lead to only modest increases in total medical expenses. However, it coincides with many other factors raising health insurance premiums,” writes Jeff Levin-Scherz.
    stat · 2mo ago
  • Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
    What Hawaii's wildfires can teach the nation about health recovery, 4.5 million people disenrolled from SNAP, and more health news
    stat · 2mo ago
  • Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer
    “In truth, I don’t anticipate prescribing patterns changing immediately,” cardiologist Vishal Khetpal writes of the new cholesterol drug Lipfendra.
    stat · 2mo ago
view all news mentions →
brand
Testosterone Par
generic
testosterone
indication
Secondary (Hypogonadotropic) Hypogonadism
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?